EOLS earnings analysis
What we found in EOLS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Evolus, Inc. reported a net revenue of $73.1 million for Q1 2026, a 6.7% increase from $68.5 million in Q1 2025, primarily driven by the launch of its Evolysse® product line. However, the company faced a net loss of $10.7 million, less than the $18.9 million loss from the previous year, reflecting improved operating efficiency. The gross profit margin decreased slightly from 68.1% to 66.9% year-over-year, amid rising costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Total revenue increased by 6.7% to $73.1 million compared to $68.5 million in Q1 2025.
- Reduced Losses
- Net loss decreased to $10.7 million in Q1 2026 from $18.9 million in the same quarter last year.
- Segment Performance
- Product revenue grew from $68.1 million to $72.7 million, contributing significantly to overall revenue.
- Improved Cash Flow
- Cash used in operating activities decreased to $10 million from $15.6 million year-over-year.
- Debt Management
- Entered a $30 million revolving credit facility to manage cash flow, providing financial flexibility.
- Cost Reduction Efforts
- Selling, general and administrative expenses decreased by 8.2% to $52.0 million from $56.6 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Accumulated Deficit
- Accumulated deficit reached $671.7 million as of March 31, 2026, limiting future operational flexibility.
- Regulatory Risks
- Potential changes in trade tariffs could adversely impact product import costs and consumer sentiment.
- Product Development Dependence
- Dependence on Symatese for regulatory approval of the Evolysse® product line poses a risk to future revenues.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.16
- Gross margin
- 66.9%
- Segment
- Jeuveau®
- Segment
- Evolysse®
What they said about what is next.
Outlook deferred to next earnings press release.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EOLS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever